Navigation Links
Alzheimer's vaccine clears plaque but has little effect on learning and memory impairment
Date:4/4/2008

Irvine, Calif., April 4, 2008 -- A promising vaccine being tested for Alzheimer's disease does what it is designed to do -- clear beta-amyloid plaques from the brain -- but it does not seem to help restore lost learning and memory abilities, according to a University of California, Irvine study.

The findings suggest that treating the predominant pathology of Alzheimer's disease -- beta-amyloid plaques -- by itself may have only limited clinical benefit if started after there is significant plaque growth. However, a combination of vaccination with therapies that also target related neuron damage and cognitive decline may provide the best treatment opportunity for people with this neurodegenerative disease. Study results appear in the April 2 issue of the Journal of Neuroscience.

"We've found that reducing plaques is only part of the puzzle to treat Alzheimer disease," said study leader, UC Irvine neurobiologist Elizabeth Head. "Vaccines such as this one are a good first step for effective Alzheimer's treatment, but complimentary treatments must be developed to address the complexity of the disease."

Head and colleagues studied for a two-year period in aging canines the effect of a vaccine that is currently under clinical development for treating patients with Alzheimer's disease. The vaccine contains the beta-amyloid 1-42 protein and stimulates the immune system to produce antibodies against this same protein that is in the brain plaques. Dogs are used for such studies because beta-amyloid plaques grow naturally in their brains and they exhibit cognitive declines similar to those seen in humans.

After the aged dogs with beta-amyloid-plaque growth were immunized (which is similar to starting a treatment in patients with Alzheimer's disease), the researchers found, in comparison with non-treated aged dogs, little difference in the results of behavioral tests that measure cognitive loss. Later, brain autopsies showed that although plaques had been cleared from multiple brain regions -- including the entorhinal cortex, a region of the brain involved with learning and memory and primarily affected by Alzheimer's -- damaged neurons remained.

Head said this discovery helps explain why there was little difference in the behavioral test results between immunized and nonimmunized dogs. In addition, she added, it implies that after clearing beta-amyloid plaques from the brain, the next step is to repair these neurons. This approach will be critical for treating and reversing the effects of the Alzheimer's disease.

Currently, Head and her colleagues are developing approaches to repair these damaged neurons and hope to test them clinically.


'/>"/>

Contact: Tom Vasich
tmvasich@uci.edu
949-824-6455
University of California - Irvine
Source:Eurekalert

Related medicine news :

1. Alzheimers Research Target May Be a Dead End
2. FDA OKs New Rotavirus Vaccine
3. Vaccine Induced Inflammation Linked to Epidemic of Type 2 Diabetes and Metabolic Syndrome
4. FDA APPROVES ROTARIX(R) [Rotavirus Vaccine, live, oral], THE FIRST VACCINE LICENSED TO COMPLETE THE ROTAVIRUS IMMUNIZATION SERIES BY FOUR MONTHS OF AGE
5. Clinical trial will test new HIV/AIDS vaccine
6. Researchers Successfully Test Ebola Vaccines
7. MITOCHONDRIAL DYSFUNCTION, VACCINES AND AUTISM: 1 in 50 Children Could Be at Risk
8. HIV Vaccine Funding: Enough is Enough, Says AHF in Baltimore Sun
9. NIAID to convene HIV Vaccine Summit
10. Study Finds Single Dose of Iomai Patch With Pandemic Flu Vaccine Achieves Protective Levels
11. UNC, Harvard develop inhaled TB vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... ... for knees, ankles, and elbows. Engineered with athletes in mind, OMNIFORCE offers ... (opposed to ineffective circular knitting, common in the industry) produces premium flat-knit ...
(Date:5/4/2016)... British Columbia – , ... ... Wimmzi , a manufacturer of innovative infant and child products, today ... toys. But their ability to help babies deal with teething pain ... FDA approved, contain no toxic gels, and are BPA-, PVC-, and ...
(Date:5/4/2016)... California (PRWEB) , ... May 04, 2016 , ... With ... Research (AACR) honors the month of May as National Cancer Research Month. According to ... million new diagnoses of cancer with predications of one in four Americans dying as ...
(Date:5/4/2016)... , ... May 04, 2016 , ... Over 40 athletic ... in the state capitol for the annual “Hike to Harrisburg” advocacy day. The ... The Winter Group, PATS lobby Group. The goal for the day was to ...
(Date:5/4/2016)... ... May 04, 2016 , ... International Conference on ... July 25-27, 2016 at Las Vegas. It aims to bring together academicians, scientists, ... and research organizations across the globe; making the conference a perfect platform to ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 2016 Research and ... Acute Ischemic Stroke Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Stroke Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Ischemic Stroke epidemiology, Acute ...
(Date:5/3/2016)... , May 3, 2016 BioNovus Innovations ... Institute for Advancing Medical Innovation (IAMI) today announced ... drugs, diagnostics and medical devices. An ... with rights to license, develop and commercialize medical ... "This partnership represents a significant advance ...
(Date:5/3/2016)... 3, 2016   BIOTRONIK , a leader ... Food and Drug Administration (FDA) approval of Iperia ... heart failure patients with access to diagnostic magnetic ... remote monitoring with daily automatic transmission and closed ... in response to physiological demands. ...
Breaking Medicine Technology: